Abstract

Sepsis and septic shock result in impaired microcirculation and red blood cell rheology which lead to tissue hypoxia and multi-organ failure. Early administration of triiodothyronine prevents tissue hypoxia in experimental sepsis. In this context, a clinical trial was initiated to test the efficacy of acute triiodothyronine administration to combat tissue hypoxia in critically ill COVID19 patients. Here, we provide preliminary data from interim analysis of this study showing a novel acute effect of triiodothyronine on erythrocyte sedimentation rate which may have an important therapeutic impact on red blood cell rheology and tissue hypoxia in sepsis and particular in COVID19 critical illness.

Trial registration: ClinicalTrials.gov, NCT04348513. Registered 16 April 2020, https://clinicaltrials.gov/ct2/show/NCT04348513

中文翻译：

---

COVID-19危重患者的急性三碘甲状腺原氨酸治疗和红细胞沉降率（ESR）：一种新的关联？

摘要

败血症和败血性休克会导致微循环和红细胞流变学受损，从而导致组织缺氧和多器官衰竭。三碘甲状腺原氨酸的早期给药可防止实验性败血症中的组织缺氧。在这种情况下，启动了一项临床试验，以测试急性三碘甲腺原氨酸给药对抗重症 COVID19 患者组织缺氧的功效。在这里，我们提供了本研究中期分析的初步数据，显示三碘甲腺原氨酸对红细胞沉降率的一种新的急性影响，这可能对脓毒症中的红细胞流变学和组织缺氧具有重要的治疗影响，特别是在 COVID19 危重疾病中。

试验注册：ClinicalTrials.gov，NCT04348513。2020 年 4 月 16 日注册，https://clinicaltrials.gov/ct2/show/NCT04348513